Caribou Biosciences plans major workforce reduction, halts CAR-T programs
CRBU•Caribou Biosciences plans to halt development of vispa-cel and discontinue CB-011, while launching a strategic review that may consider a merger or sale. It expects most workforce reductions to be completed in the fourth quarter of 2026; cash, cash equivalents and marketable securities totaled $113.8 million as of June 30, 2026.
1. Programs to be halted
Caribou plans to halt development of vispa-cel for relapsed or refractory B-cell non-Hodgkin lymphoma, despite the program being positioned for a pivotal trial. The company is also discontinuing CB-011 for relapsed or refractory multiple myeloma, citing a tougher financing market for allogeneic CAR-T therapies.
2. Strategic review and cuts
Caribou launched a strategic review aimed at maximizing stockholder value, weighing options including a merger or sale. Workforce and cost reductions are planned, with most workforce cuts expected to be completed in the fourth quarter of 2026. The company reported $113.8 million in cash, cash equivalents and marketable securities as of June 30, 2026.
